Earnings ·
BioHarvest Sciences Inc. filed its unaudited interim condensed consolidated financial statements for the three and six…
BHSTBioharvest Sciences Inc.
BioHarvest Sciences Inc. filed its unaudited interim condensed consolidated financial statements for the three and six months ended June 30, 2026. The company reported revenues of $17,344 thousand for the first half of 2026, a 5.9% increase from $16,375 thousand in the prior year period. Net loss widened to $6,356 thousand from $6,418 thousand previously, driven by higher research and development expenses of $3,058 thousand and sales and marketing costs of $8,506 thousand. Gross margin remained stable at 58%. Cash and cash equivalents decreased to $15,211 thousand from $23,025 thousand at year-end 2025 due to operating losses and capital expenditures. The company continues to face substantial doubt regarding its ability to continue as a going concern due to historical operating losses and reliance on external financing. BioHarvest Sciences Inc. is a biotechnology company that utilizes Botanical Synthesis Platform Technology to produce plant-based active ingredients for nutraceutical, pharmaceutical, and cosmeceutical applications.